Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. (Nasdaq: TKNO) is a producer of critical reagents for the life sciences industry, with news flow that reflects its role in supporting therapies, vaccines, molecular diagnostics, and cell therapies. Company updates often highlight performance across its Lab Essentials and Clinical Solutions product groupings, as well as developments in its manufacturing platform and collaborations.
Investors and observers following TKNO news can expect regular earnings announcements and related commentary on revenue trends, gross margin, operating expenses, and non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow. These updates are typically furnished through press releases and accompanying Form 8-K filings that discuss quarterly and full-year financial results and provide revenue breakdowns by Lab Essentials, Clinical Solutions, and Other categories.
Teknova’s news also includes product and partnership announcements. A notable example is its collaboration with Pluristyx, Inc. on the PluriFreeze cryopreservation system, where Teknova serves as the exclusive manufacturer and distributor in the United States and Canada. Press releases describe how this system is intended to streamline the manufacture of next-generation allogeneic cell therapies through synthetic, animal-origin-free cryopreservation and wash media.
Additional news items cover guidance for upcoming periods, descriptions of the company’s participation in investor conferences, and reminders about scheduled earnings calls and webcasts. For readers interested in how a life science reagents supplier communicates its financial performance, product evolution, and strategic collaborations, the TKNO news feed provides an ongoing record of Teknova’s public disclosures and corporate milestones.
Alpha Teknova (Nasdaq: TKNO) released its Q1 2024 financial results, reporting a 2% increase in total revenue to $9.3 million compared to $9.1 million in Q1 2023. Lab Essentials revenue remained flat at $7.3 million, while Clinical Solutions revenue rose 7% to $1.7 million. The company launched the Build-Tek™ Solutions, an innovative product allowing quick buffer formulation for early-stage therapy development. Gross profit declined to $2.2 million due to increased overhead costs. Operating expenses dropped to $10.2 million, leading to a net loss reduction from $8.8 million in Q1 2023 to $8.1 million in Q1 2024. Adjusted EBITDA improved to negative $3.8 million from negative $6.1 million. Teknova reaffirmed its 2024 revenue guidance of $35-38 million and free cash outflow of less than $18 million.
Teknova has launched Build-Tek Solutions, a custom configurator providing high-quality, customizable buffers for early-stage experiments with quick turnaround times. They also introduced the AAV-Tek AAV Stabilizer, enhancing capsid yield by up to 50% and safeguarding product integrity. The products aim to support research scientists in advancing science and therapy development.
Alpha Teknova, Inc. (“Teknova”) will report its financial results for the first quarter of 2024 on May 13, 2024. Teknova is a leading producer of critical reagents for therapies, vaccines, and diagnostics. The company will host a webcast and conference call on the same day. Investors can access the live webcast from the Investor Relations section of the Teknova website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.